CAFFEINE METABOLISM IN CYSTIC-FIBROSIS - ENHANCED XANTHINE-OXIDASE ACTIVITY

被引:21
作者
HAMELIN, BA [1 ]
XU, KY [1 ]
VALLE, F [1 ]
MANSEAU, L [1 ]
RICHER, M [1 ]
LEBEL, M [1 ]
机构
[1] UNIV LAVAL, ECOLE PHARM, PHARMACOCINET LAB, QUEBEC CITY G1K 7P4, PQ, CANADA
关键词
D O I
10.1038/clpt.1994.173
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study objective: To characterize the activities of the P450 mixed-function oxidase C gamma P1A2 as well as the cytosolic enzymes N-acetyltransferase and xanthine oxidase using caffeine as a probe in children with cystic fibrosis compared to age-matched healthy control subjects. Methods: After administration of caffeine (cola beverage) to 12 children with cystic fibrosis (age range, 5 to 11 years) and 12 healthy control subjects (age range, 5 to 12 years), urine was collected for 4 hours. Caffeine metabolites were determined by HPLC, and urinary caffeine metabolite ratios were computed to determine liver enzyme activities. In addition, a blood sample was used to detect cystic fibrosis mutant alleles by polymerase chain reaction. Results: The indexes for C gamma P1A2, N-acetyltransferase, and 8-hydroxylation were similar in both groups of subjects. In contrast, there was a significant difference in the frequency distribution of the xanthine oxidase activity between the tao groups. Nine of 12 patients with cystic fibrosis but only one of 12 healthy volunteers had xanthine oxidase activities above 0.42 (Kolmogorov-Smirnov two-sample test, p < 0.01). Conclusions: Differences in xanthine oxidase may have clinical implications with regard to interindividual variation in xenobiotic biotransformation and the exposure to lung tissue-damaging oxygen radicals. Hepatic enzyme activities appear to be selectively altered in patients with cystic fibrosis.
引用
收藏
页码:521 / 529
页数:9
相关论文
共 49 条
[1]   MATURATION OF CAFFEINE ELIMINATION IN INFANCY [J].
ARANDA, JV ;
COLLINGE, JM ;
ZINMAN, R ;
WATTERS, G .
ARCHIVES OF DISEASE IN CHILDHOOD, 1979, 54 (12) :946-949
[2]   PURIFICATION AND FUNCTIONAL RECONSTITUTION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) [J].
BEAR, CE ;
LI, CH ;
KARTNER, N ;
BRIDGES, RJ ;
JENSEN, TJ ;
RAMJEESINGH, M ;
RIORDAN, JR .
CELL, 1992, 68 (04) :809-818
[3]   THE INFLUENCE OF INSULIN-DEPENDENT DIABETES ON THE METABOLISM OF CAFFEINE AND THE EXPRESSION OF THE DEBRISOQUIN OXIDATION PHENOTYPE [J].
BECHTEL, YC ;
JOANNE, C ;
GRANDMOTTET, M ;
BECHTEL, PR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (04) :408-417
[4]  
BERTHOU F, 1991, DRUG METAB DISPOS, V19, P561
[5]  
BONATI M, 1988, ISI ATLAS-PHARMACOL, V2, P33
[6]  
BOSSO JA, 1989, PEDIATR PULM, V8, P157
[7]   HUMAN CYTOCHROME P-450PA (P-450IA2), THE PHENACETIN O-DEETHYLASE, IS PRIMARILY RESPONSIBLE FOR THE HEPATIC 3-DEMETHYLATION OF CAFFEINE AND N-OXIDATION OF CARCINOGENIC ARYLAMINES - (AROMATIC-AMINES HETEROCYCLIC AMINES CARCINOGEN METABOLISM) [J].
BUTLER, MA ;
IWASAKI, M ;
GUENGERICH, FP ;
KADLUBAR, FF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) :7696-7700
[8]   DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES [J].
BUTLER, MA ;
LANG, NP ;
YOUNG, JF ;
CAPORASO, NE ;
VINEIS, P ;
HAYES, RB ;
TEITEL, CH ;
MASSENGILL, JP ;
LAWSEN, MF ;
KADLUBAR, FF .
PHARMACOGENETICS, 1992, 2 (03) :116-127
[9]   A URINARY METABOLITE RATIO THAT REFLECTS SYSTEMIC CAFFEINE CLEARANCE [J].
CAMPBELL, ME ;
SPIELBERG, SP ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (02) :157-165
[10]   MATURATION OF CAFFEINE METABOLIC PATHWAYS IN INFANCY [J].
CARRIER, O ;
PONS, G ;
REY, E ;
RICHARD, MO ;
MORAN, C ;
BADOUAL, J ;
OLIVE, G .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (02) :145-151